We are excited to announce that Eagle IP has been named as a finalist for the Life Sciences Patent Network (LSPN) Awards USA 2025 in the following categories:   

  1. Inspiring Woman of the Year: This nomination recognizes our President and Managing Director, Ms. Jennifer Che, for her outstanding leadership, innovation, and dedication to empowering others in the industry.  
  1. International Firm of the Year: This nomination recognizes the excellence and achievements of international firms, such as Eagle IP

We are truly honored to be shortlisted in two different categories for the LSPN Awards USA 2025!  This award recognizes "excellence, innovation, and leadership in life sciences IP" and tries to identify individuals and organizations that are "shaping the future of pharmaceutical and biotech patent protection." This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration. 

You can see all the finalists here

我们的过去活动

Recommended Insights

Finally a unified “Court of Appeal” for technology IP in China

2019年1月22日
On October 26, 2018, China’s Supreme People’s Court (“SPC”) received approval to establish a specialized intellectual property court within the SPC to handle appeal cases involving technology-related IP for both civil (e.g., patent infringement) and administrative (e.g., patent invalidity) judgments. Technology-related IP includes invention patents, utility models, new plant species, IC design, trade secret, software, […]

US vs CN: Foreign Filing License Requirements

2022年11月9日
In China, foreign filing requirements are generally very similar to the US — a foreign filing license is required if a foreign application is to be filed first for an invention made in the country. The Chinese equivalent to the US foreign filing license is called a confidentiality examination for foreign filing. According to Chinese […]

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right